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Introduction. With the standard treatment of chronic hepatitis C, sustained virological response (SVR) can be achieved only in
half of all patients. Interleukin-28B appears to be involved in the control of HCV infection, and the genetic polymorphism of
the encoding IL-28B gene may determine the eﬃcacy of clearance of HCV. The aim of this paper was to detect IL-28B gene
polymorphism in Latvia and to analyze therapy results. This is the ﬁrst study on IL-28B gene polymorphism in Latvia. Material
andMethods.Therewere159chronicviralhepatitisCpatientsincludedinthestudy.InordertodetectIL-28Bgenepolymorphism,
we used molecular biology techniques and methods: classical DNA separation, ampliﬁcation by PCR, and standard sequencing.
Genotype was deﬁned as CC, CT, TC, or TT type. 142 patients were treated with the standard of care treatment. Results were
analyzed according to IL-28B polymorphism. Results. There were 53 patients (33%) with CC genotype, 84 patients (53%) with
CT/TC genotype, and 22 patients (14%) with TT genotype. 34 patients (74%) in CC genotype subgroup achieved SVR versus 50
patients (52%) in non-CC subgroups. In patients with genotype 1, SVR was achieved in 16 patients (84%) in CC subgroup versus
30 patients (47.6%) in non-CC subgroups, P = 0.007. Conclusions. The most common genotype of IL28B in Latvia is CT/TC, with
an incidence of 53%. Patients with CC genotype achieved SVR more often than CT or TT subgroups. IL28B gene polymorphism
therefore is a strong predictor of treatment result.
1.Introduction
Chronic viral hepatitis C is one of the most serious chronic
infections aﬀecting 170 million people worldwide. In Europe
more than 9 million people are infected with this virus [1].
The prevalence of hepatitis C virus (HCV) infection is also
relatively high in Latvia. Antibodies are found in 2.4% of the
population, with HCV-RNA prevalence of 1.7% of general
population [2]. The outcome of HCV infection varies from
spontaneousviralclearance,symptomfree-HCVcarrierstate
to chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Some individuals have rapidly progressive liver disease while
others remain in good health for many years. The reasons
for diﬀerent outcomes are poorly understood. There are a
lot of factors such as viral kinetics, immune mechanisms,
environmentalfactors,andpatient-relatedfactorswhichmay
be responsible for the various HCV-related outcomes.
Hepatitis C virus spreads mainly via blood. Risk factors
for infection include intravenous and intranasal drug use,
nonsterile tattooing, manicure and pedicure procedures,
as well as virus transmission vertically from mother to
child, and during sexual intercourse. Dialysis patients appear
to be at increased risk of infection as do alcoholics [1,
3]. In developing and transitional economy countries, the
nosocomial transmission of new hepatitis C virus (HCV)
infections is a major problem due to reuse of contaminated
or inadequately sterilized syringes and needles used in2 Hepatitis Research and Treatment
medical, paramedical, and dental procedures; an estimated
2.3–4.7 million new infections occur each year [1].
Current standard of care treatment involves combination
therapy with hopes of eﬀective virus eradication resulting
in a sustained virological response (SVR) and thereby
stopping the progression of disease. With the combination
of pegylated alpha interferon and ribavirin, a sustained
virological response can be achieved in only 54 to 63% of
patients [4].
Cytokines have a role in the mechanisms of host
defense against infectious agents. They induce inﬂammatory
responses that can lead to tissue injury and serve as antiviral
eﬀectors as well. Cytokine synthesis is regulated by genetic
mechanisms resulting in diﬀerences between individuals in
their ability to produce cytokines. This individual variability
may be due to single-nucleotide polymorphisms within
the coding regions of cytokine genes. Cytokine genes
are polymorphic, and some of these variants modify the
production of the speciﬁc cytokines thereby aﬀecting the
host immune response. In HCV infection, secretion of
inappropriate amounts of cytokines may be associated with
developments of chronic disease or resistance to interferon
(IFN) treatment. Interleukin-28B (IL-28B), named also as
interferon λ-3, has been shown to be involved in the control
of HCV infection, and the genetic polymorphism of the
encoding IL-28B gene may determine the clearance of HCV.
TheIL-28Bgeneonhumanchromosome19qwasdiscovered
in 2003, using the genomic screening process in which the
entire human genome was scanned for putative genes [5, 6].
IL-28B gene polymorphism currently seems to be one of
the strongest predictors of SVR [7].
T h ea i mo ft h i ss t u d yw a st od e t e c tI L - 2 8 Bg e n e
polymorphism in chronic hepatitis C patients in Latvia and
to analyze therapy results in patients with diﬀerent IL-28B
gene polymorphisms. This is the ﬁrst study carried out in
Latvia,intheBalticStatesandlikelyinEasternEuropeforthe
detection of Interleukin 28B gene polymorphism and how it
impacts on hepatitis C treatment.
2.MaterialandMethods
There were 159 chronic viral hepatitis C patients included
in the study. All chronic viral hepatitis C patients who
c a m et oI n f e c t o l o g yC e n t e ro fL a t v i af o rah e p a t o l o g i s t ’ s
consultation were tested. Patients had to sign the informed
patients’ consent prior to testing. In order to detect IL-28B
gene polymorphism—rs12979860 genotype frequency we
used molecular biology methods: classical DNA separation
from blood samples by phenol, ampliﬁcation by PCR,
and standard sequencing by Big Dye (Applied Biosystems).
Genotype was deﬁned as CC, CT, TC, or TT type.
142 patients were treated with the standard of care
therapy-pegylated interferon in combination with ribavirin.
80 percent of patients received pegylated interferon α2a and
20 percent—α2b. We analyzed therapy results according to
IL-28B gene polymorphism. All patients were divided into
3 subgroups: CC, CT/TC, and TT. Diﬀerent patient factors,
laboratory tests, viral kinetics, and treatment response were
analyzed. In terms of therapy result patients were divided
CC
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Figure 1: Distribution of IL-28B gene polymorphism.
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Figure 2: Treatment results depending on IL-28B gene polymor-
phism.
into 3 groups: responders, nonresponders, and interrupters.
Respondersachievedsustainedvirologicalresponseandwere
HCV-RNA negative at the end of therapy and 24 weeks after
stoppingtreatment.NonresponderswereHCV-RNApositive
at week 12 (null responders), at the end of therapy (partial
responders) or at week 24 after stopping therapy (relapsers).
Interrupters stopped therapy due to ﬁnancial reason (there is
75% drug reimbursement for chronic hepatitis C treatment,
25% of treatment expenses are covered by patient) or
due to unknown reason. HCV-RNA was measured using
polymerase chain reaction (PCR), AMPLICOR, version 2.0;
Roche,USA.Viralloadforgenotype1patientswasmeasured
at baseline and at week 12 on treatment. Liver biopsy was
performed for 126 (88.7%) patients, and morphological
assessment was done using Knodell’s HAI index. There wereHepatitis Research and Treatment 3
Table 1: Baseline characteristics of the patient’s proﬁle.
CC NON-CC TOTAL
Average age, years 35 37 37 (18–68)
No. of patients, >40years 15 (33%) 40 (42%) 54 (39%)
Male sex 27 (59%) 57 (59%) 84 (59%)
BMI, kg/m2 25.2 26.2 25.9
BMI, >30kg/m2 5 (11%) 12 (13%) 17 (12%)
Genotype 1 21 (46%) 66 (69%) 87 (61%)
Genotype 2, 3 25 (54%) 30 (31%) 55 (39%)
HCV-RNA, ×106 IU/mL (Genotype1) 2.78 2.19 2.33
HCV-RNA, >600,000IU/mL (Genotype 1) 18 (39%) 47 (49%) 65 (46%)
ALT, U/L 112 (17–325) 104 (22–447) 106 (17–447)
ALT, >ULN 43 (93%) 85 (88%) 128 (90%)
GGT, U/L 46.8 (9–228) 88 (6–526) 75 (6–526)
GGT, >ULN 11 (24%) 40 (42%) 51 (36%)
Cholesterol, mM/L 4.14 (2.09–7.35) 4.6 (2.46–8.17) 4.48 (2.09–8.17)
Triglycerides, mM/L 1.17 (0.28–4.06) 1.17 (0.3–5.44) 1.11 (0.28–5.44)
Liver ﬁbrosis∗ (Knodell)
F0
F1
F3
F4
0.975 (0–3)
9 (21.9%)
28 (68.3%)
4 (9.7%)
0
1.2 (0–4)
21 (24.7%)
47 (55.3%)
12 (14%)
5 (5.9%)
1.13 (0–4)
30 (23.8%)
75 (59.5%)
16 (12.7%)
5 (3.9%)
HAI index∗ (Knodell) 6.44 (1–12) 6.54 (2–13) 6.5 (1–13)
Steatosis∗ > grade 0 34 (83%) 65 (76.5%) 99 (78.6%)
SVR 34 (74%) 50 (52%) 84 (59%)
∗Missing data: histology n = 11 (non-CC), n = 5 (CC).
Table 2: Treatment results in patients with genotype 1 depending on IL-28B gene polymorphism.
IL-28B genotype
Total P
CC Non-CC
Therapy result
Genotype 1
Nonresponders Count
% within IL-28B genotype
3
15,79%
33
52,38%
36
43,90%
Responders Count
% within IL-28B genotype
16
84,21%
30
47,62%
46
56,10% 0.007367
Total Count
% within IL-28B genotype
19
100%
63
100%
82
100%
not statistically signiﬁcant diﬀerences between groups with
regard to ﬁbrosis stage and HAI index.
Statistical processing of data was done using SPSS v.15.0
andMicrosoftOﬃceExcelv.11.Comparisonbetweengroups
wasperformedusingPearsonChi-SquaretestorFisher’sExact
test. Signiﬁcance was deﬁned at a P value of less than 0.05.
Study was approved by the Independent Ethics Com-
mittee for clinical investigation of drugs and pharmaceutical
products in Latvia.
Study was performed during the 2009–2011 at the State
Agency “Infectology center of Latvia.”
3. Results andDiscussion
There were 53 patients (33%) with CC genotype, 84 patients
(53%) with CT (83 patients) or TC (1 patient) genotype, and
22 patients (14%) with TT genotype among chronic viral
hepatitis C patients in Latvia (Figure 1).
142 patients were treated with the standard of care
therapy-pegylated interferon in combination with ribavirin
Table 1.
AllincludedpatientswereCaucasians,amajorityofthem
male (59%) and genotype 1 (61%) patients.
34 patients (74%) in CC genotype subgroup achieved
SVR versus 50 patients (52%) in non-CC subgroup—41
patientinCT/TCand9patientsinTTsubgroups.Therewere
4 patients (8.7%) nonresponders in CC subgroup (all were
relapsers: 3 of them with HCV genotype 1, 1 patient—HCV
genotype2)versus35patients(36.5%)innon-CCsubgroups
(7 patients null responders, HCV genotype 1, 13 patients
partial responders: 11 patients HCV genotype 1, 2 patients4 Hepatitis Research and Treatment
HCV genotype 3, and 15 patients relapsers, HCV genotype
1); the diﬀerences were statistically signiﬁcant, P = 0.002,
Pearson Chi-Square test (Figure 2).
There was statistically signiﬁcant diﬀerence also in
patients with genotype 1 HCV infection—SVR which was
achieved in 16 patients (16/19, 84%) in CC subgroup versus
30 patients (30/63, 47.6%) in non-CC subgroups, P = 0.007,
Fisher’s Exact test (Table 2).
The last two decades have seen major advances in HCV
treatment options and patient management. However, the
standard of care treatment (peg interferon plus ribavirin)
is eﬀective in less than half of chronically infected HCV
genotype 1 treatment na¨ ıve patients, regardless of the type
or dose of peg interferon used [8–10].
There are many factors inﬂuencing therapy result; some-
times it is hard to understand which of them is the most
essential. During recent years there are publications of
interleukin 28B gene polymorphism as a strong predictor
of SVR in patients treated with pegylated interferon and
ribavirin.
According to Thompson et al. data [7], published in
2010, IL-28B gene polymorphism between Caucasians is
distributed as follows: CC 37%, CT 51%, and TT 12%. In
Latvia majority of people are Caucasians. These results are
similar to our data: CC33%, CT 53%, and TT 14%. SVR
rates achieved in Thompson’s study are 69% of patients in
CC group, 33% in CT group, and 27% in TT group [7].
In our study these data are diﬀerent: 74%, 55%, and 43%,
respectively. This diﬀerence is probably because of diﬀerent
patient proﬁle: we included all genotype patients (61% were
1st genotype), but in Thompson’s study there were only 1st
genotype patients included, and it is already known that SVR
rates are better in patients with 2nd and 3rd genotypes.
Par et al. [11] have published data in CEMED where CC
genotype in HCV patients was noted with signiﬁcantly lower
frequency than in healthy controls (79/281, 28.11% versus
54/104, 51.92%), suggesting a protective role of this variant.
Also patients treated with pegylated interferon and ribavirin
with CC genotype achieved SVR at signiﬁcantly higher rates,
than those with TT genotype (25/46, 54.34% versus 7/24,
29.16%).
If we analyze only HCV genotype 1 patients, our data
shows slightly better results in comparison with Thompson
and Par studies. In CC subgroup SVR was achieved in 69%
(Thompson), 54.34% (Par), and 84% in our study.
In addition, in our study we analyzed other diﬀerent
treatment eﬃcacy factors, including number of missed
treatmentdoses.80percentofpatientsdidnotmissanydose.
We have to stress that chronic viral hepatitis C patients are
paying 25% of treatment costs themselves in Latvia, and 75%
is covered by sick fund. Actually they are highly motivated to
use assigned medicine.
IntermsofthehigherSVRonCCgenotypepatientsfrom
the study cohort when compared with Thompson et al.’ 2010
study, this cohort had younger patients with lower BMI’s,
but with higher advanced ﬁbrosis and steatosis rate. Besides
that, ﬁbrosis stage was higher in nonresponders group, in
comparison to responders group, P = 0.029, Mann-Whitney
U-test. These factors inﬂuence SVR rates in hepatitis C
patients and could have played a role as well in the diﬀerence
from virologic responses.
Our study is the ﬁrst study in Latvia and Baltics done on
interleukin B28 gene polymorphism with ﬁndings similar to
other studies involving Caucasian patients.
4. Conclusions
While the most prevalent genotype of IL-28B in Latvia is
CT, the most favorable response to treatment and SVR is
seen in genotype CC patients. IL-28B gene polymorphism is
therefore a strong predictor of response to therapy.
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